

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Noxopharm Limited (ASX: NOX)
ABN	50 608 966 123

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Gisela Mautner
Date of appointment	1 February 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
265,208 Unlisted Options under the NOX Incentive Plan where: <ol style="list-style-type: none">130,208 vested unlisted options exercisable at \$0.32, expiring 16 December 2023; and135,000 vested unlisted options exercisable at \$0.55, expiring 6 November 2024.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities N/A
--	--

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Under the terms of the Executive Services Agreement (ESA) between Noxopharm Limited and Dr Mautner as announced to the ASX on 5 January 2022, Dr Mautner has been offered options as part of her remuneration package.
Nature of interest	Options as part of remuneration package.
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	2 million options at a strike price of \$0.54 that vest subject to certain performance hurdles and expire in 4 years. These options are subject to shareholder approval to be voted on at the next shareholder meeting.

+ See chapter 19 for defined terms.